A NOVEL PIPELINE

Program
Target
Discovery Proof of concept pre-clinical Clinical studies

We believe that CEACAM5/6-targeting therapies have the potential to transform the cancer therapeutic landscape. That’s why our three most advanced antibody-derived therapies all target CEACAM5/6-positive cancers.

Our CT109 antibody specifically targets a unique epitope on a validated tumor-specific antigen. Thus far, our research (and that of collaborators) has shown:

TARGETING A RANGE
OF CANCERS

The potential for CT109 to be used to target a range of epithelial cancers. An IHC screening of several different epithelial cancers (including non-small cell lung, colorectal, and pancreatic cancer) shows that CT109 binds exclusively to cancer cells with undetectable expression in normal tissues.

REDUCTION IN
TUMOR GROWTH

Significant and dose-dependent reduction in tumor growth in an in vivo xenograft model using our CT109 ADC. Additionally, Stromatis Pharma has developed an arsenal of CT109 ADCs with different payloads (SN-38, MMAF and more) shown to target and kill the cells that express the antigen in vitro.

INCREASED
ADC EFFICACY

Successful improvement of efficacy following modifications to the CT109 ADC. By adjusting the drug to antibody ratio (DAR) for the CT109 ADC, we show that the tumor-killing capacity of our drug is significantly improved. Moreover, the CT109 ADC can be easily modified with various linkers to improve the efficacy of drug delivery.

POTENTIAL CAR-T
APPLICATION

Dramatic killing of cancer cells in vivo using CAR-T therapies. In collaboration with Dr. Avery Posey at the University of Pennsylvania, treatment with CT109 based CAR-T therapy in a tumor xenograft model was associated with pronounced PDAC tumor regression, including complete responses among a subset of the CT109 CAR-T treated groups. CT109 CAR-T killing is highly antigen specific, as deletion of the antigen in target cells effectively eliminates off target effects.

Our vision is not limited to this sphere alone. We are building a proprietary portfolio of equally specific antibodies against other validated protein targets, and, by extension, different cancer indications. With the help of our partners, investors, and collaborators, Stromatis Pharma aims to combat an even wider range of cancers with few targeted treatment options.

STROMATIS PHARMA’S PARTNERSHIPS:

Stromatis is partnering with a wide range of pioneers in the oncology realm, including Dr. Daniel Von Hoff, Dr. James Michael Pierce, and Dr. Haiyong Han. Through their support, CT109 ADCs are being developed through pre-clinical studies, including proof-of-principle studies currently underway. Additionally, CAR-T preclinical development using our CT109 antibody was performed in collaboration with Dr. Avery Posey.

We continue to work with industry leaders to develop best-in-class antibody-derived therapeutics.